A new cholesterol drug from the pharmaceutical company, Amgen Inc., may steer doctors away from prescribing a medication tied to Lipitor diabetes complications in a rising number of lawsuits against its manufacturer, according to TechTimes.com.

An article on April 1st reports that the new drug, evolocumab, mimics the effects of a genetic mutation to lower LDL (bad cholesterol) in the blood. Clinical trials have shown that the medication may reduce blood fat levels; a finding that has already been backed by data from three large studies at the 64rd Annual Scientific Session of the American College of Cardiology (ACC). Findings of the research were released on March 30th and found patients who took the new medication reduced their LDL levels by as much as 66 percent.

According to one study that directly compared the effectiveness of evolocumab, it was found that patients taking the Amgen drug for a year experienced a 57 percent reduction in LDL levels than those taking a placebo. Patients already taking a drug involved in dozens of Lipitor lawsuit filings saw a 49 percent lowered rate of bad cholesterol levels.

The findings of a Mendel study published March 29th in the Journal of American College of Cardiology further highlighted the potential benefits of evolocumab. Individuals with high cholesterol saw a 57 percent reduced rate of bad cholesterol levels, according to the research, within the first three months of use.

Patient benefit only continued to increase after that. “At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks,” leaders of the study wrote.

270 Cases Pending in Lipitor Lawsuit Litigation as of April 2014

Meanwhile, Lipitor lawsuits are continuing to move forward in a multidistrict litigation established for cases over the statin. Court records from April 2014 show 270 claims now filed in the U.S. District Court, District of South Carolina on behalf of individuals alleging new-onset Type 2 diabetes and other side effects. Plaintiffs further claim that Pfizer Inc. knew about these risks prior to marketing the medication, but withheld them from the general public. Many of these cases follow research published in JAMA: Internal Medicine in January 2014 that found an increased risk for Type 2 diabetes in post-menopausal women.

Filing a Lipitor Lawsuit

If you developed Type 2 diabetes after taking Lipitor, call our Firm to find out more about filing a case against its manufacturer. Call Bernstein Liebhard LLP directly at (877) 779-1414.

Published April 3, 2014 by